Epstein-Barr virus ensures B cell survival by uniquely modulating apoptosis at early and late times after infection

  1. Alexander M Price
  2. Joanne Dai
  3. Quentin Bazot
  4. Luv Patel
  5. Pavel A Nikitin
  6. Reza Djavadian
  7. Peter S Winter
  8. Cristina A Salinas
  9. Ashley Perkins Barry
  10. Kris C Wood
  11. Eric C Johannsen
  12. Anthony Letai
  13. Martin J Allday
  14. Micah A Luftig  Is a corresponding author
  1. Duke University School of Medicine, United States
  2. Imperial College London, United Kingdom
  3. Harvard Medical School, United States
  4. University of Wisconsin School of Medicine and Public Health, United States
  5. Duke University, United States

Abstract

Latent Epstein-Barr virus (EBV) infection is causally linked to several human cancers. EBV expresses viral oncogenes that promote cell growth and inhibit the apoptotic response to uncontrolled proliferation. The EBV oncoprotein LMP1 constitutively activates NFB and is critical for survival of EBV-immortalized B cells. However, during early infection EBV induces rapid B cell proliferation with low levels of LMP1 and little apoptosis. Therefore, we sought to define the mechanism of survival in the absence of LMP1/NFB early after infection. We used BH3 profiling to query mitochondrial regulation of apoptosis and defined a transition from uninfected B cells (BCL-2) to early-infected (MCL-1/BCL-2) and immortalized cells (BFL-1). This dynamic change in B cell survival mechanisms is unique to virus-infected cells and relies on regulation of MCL-1 mitochondrial localization and BFL-1 transcription by the viral EBNA3A protein. This study defines a new role for EBNA3A in the suppression of apoptosis with implications for EBV lymphomagenesis.

Data availability

The following previously published data sets were used
    1. Zhao B
    2. Zou JY
    3. Wang H
    4. Johannsen E
    5. Aster J
    6. Bernstein B
    7. Kieff E
    (2011) EBNA2 ChIP-Seq
    Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE29498).
    1. Shoresh N
    (2011) Histone modifications in LCLs (ENCODE)
    Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE29611).
    1. Snyder M
    2. Gerstein M
    3. Weissman S
    4. Farnham P
    5. Struhl K
    (2011) TF binding sites in LCLs (ENCODE)
    Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE31477).

Article and author information

Author details

  1. Alexander M Price

    Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, United States
    Competing interests
    No competing interests declared.
  2. Joanne Dai

    Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, United States
    Competing interests
    No competing interests declared.
  3. Quentin Bazot

    Molecular Virology, Division of Infectious Diseases, Department of Medicine, Imperial College London, London, United Kingdom
    Competing interests
    No competing interests declared.
  4. Luv Patel

    Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States
    Competing interests
    No competing interests declared.
  5. Pavel A Nikitin

    Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, United States
    Competing interests
    No competing interests declared.
  6. Reza Djavadian

    McArdle Laboratory for Cancer Research, University of Wisconsin School of Medicine and Public Health, Madison, United States
    Competing interests
    No competing interests declared.
  7. Peter S Winter

    Department of Pharmacology and Cancer Biology, Duke University, Durham, United States
    Competing interests
    No competing interests declared.
  8. Cristina A Salinas

    Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, United States
    Competing interests
    No competing interests declared.
  9. Ashley Perkins Barry

    Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, United States
    Competing interests
    No competing interests declared.
  10. Kris C Wood

    Department of Pharmacology and Cancer Biology, Duke University, Durham, United States
    Competing interests
    No competing interests declared.
  11. Eric C Johannsen

    McArdle Laboratory for Cancer Research, University of Wisconsin School of Medicine and Public Health, Madison, United States
    Competing interests
    No competing interests declared.
  12. Anthony Letai

    Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States
    Competing interests
    Anthony Letai, Is a paid advisor to, and his laboratory receives research sponsorship from, AbbVie, Astra-Zeneca, and Tetralogic..
  13. Martin J Allday

    Molecular Virology, Division of Infectious Diseases, Department of Medicine, Imperial College London, London, United Kingdom
    Competing interests
    No competing interests declared.
  14. Micah A Luftig

    Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, United States
    For correspondence
    micah.luftig@duke.edu
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2964-1907

Funding

National Cancer Institute (R01-CA140337)

  • Micah A Luftig

American Cancer Society (RSG-13-228-01-MPC)

  • Micah A Luftig

Wellcome (099273/Z/12/Z)

  • Quentin Bazot
  • Martin J Allday

National Institute for Dental and Cranofacial Research (R01-DE025994)

  • Joanne Dai
  • Micah A Luftig

National Institute for Allergy and Infectious Diseases (5P30-AI064518)

  • Micah A Luftig

National Cancer Institute (F31-CA180451)

  • Alexander M Price

National Institute for Dental and Cranofacial Research (R01-DE023939)

  • Eric C Johannsen

National Institute for Allergy and Infectious Diseases (T32-AI078985)

  • Reza Djavadian

National Cancer Institute (R01-CA129974)

  • Anthony Letai

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2017, Price et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,678
    views
  • 726
    downloads
  • 63
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Alexander M Price
  2. Joanne Dai
  3. Quentin Bazot
  4. Luv Patel
  5. Pavel A Nikitin
  6. Reza Djavadian
  7. Peter S Winter
  8. Cristina A Salinas
  9. Ashley Perkins Barry
  10. Kris C Wood
  11. Eric C Johannsen
  12. Anthony Letai
  13. Martin J Allday
  14. Micah A Luftig
(2017)
Epstein-Barr virus ensures B cell survival by uniquely modulating apoptosis at early and late times after infection
eLife 6:e22509.
https://doi.org/10.7554/eLife.22509

Share this article

https://doi.org/10.7554/eLife.22509

Further reading

    1. Cancer Biology
    Han V Han, Richard Efem ... Richard Z Lin
    Research Article

    Most human pancreatic ductal adenocarcinoma (PDAC) are not infiltrated with cytotoxic T cells and are highly resistant to immunotherapy. Over 90% of PDAC have oncogenic KRAS mutations, and phosphoinositide 3-kinases (PI3Ks) are direct effectors of KRAS. Our previous study demonstrated that ablation of Pik3ca in KPC (KrasG12D; Trp53R172H; Pdx1-Cre) pancreatic cancer cells induced host T cells to infiltrate and completely eliminate the tumors in a syngeneic orthotopic implantation mouse model. Now, we show that implantation of Pik3ca−/− KPC (named αKO) cancer cells induces clonal enrichment of cytotoxic T cells infiltrating the pancreatic tumors. To identify potential molecules that can regulate the activity of these anti-tumor T cells, we conducted an in vivo genome-wide gene-deletion screen using αKO cells implanted in the mouse pancreas. The result shows that deletion of propionyl-CoA carboxylase subunit B gene (Pccb) in αKO cells (named p-αKO) leads to immune evasion, tumor progression, and death of host mice. Surprisingly, p-αKO tumors are still infiltrated with clonally enriched CD8+ T cells but they are inactive against tumor cells. However, blockade of PD-L1/PD1 interaction reactivated these clonally enriched T cells infiltrating p-αKO tumors, leading to slower tumor progression and improve survival of host mice. These results indicate that Pccb can modulate the activity of cytotoxic T cells infiltrating some pancreatic cancers and this understanding may lead to improvement in immunotherapy for this difficult-to-treat cancer.

    1. Cancer Biology
    2. Immunology and Inflammation
    Almudena Mendez-Perez, Andres M Acosta-Moreno ... Esteban Veiga
    Short Report

    In this study, we present a proof-of-concept classical vaccination experiment that validates the in silico identification of tumor neoantigens (TNAs) using a machine learning-based platform called NAP-CNB. Unlike other TNA predictors, NAP-CNB leverages RNA-seq data to consider the relative expression of neoantigens in tumors. Our experiments show the efficacy of NAP-CNB. Predicted TNAs elicited potent antitumor responses in mice following classical vaccination protocols. Notably, optimal antitumor activity was observed when targeting the antigen with higher expression in the tumor, which was not the most immunogenic. Additionally, the vaccination combining different neoantigens resulted in vastly improved responses compared to each one individually, showing the worth of multiantigen-based approaches. These findings validate NAP-CNB as an innovative TNA identification platform and make a substantial contribution to advancing the next generation of personalized immunotherapies.